Article Sidebar
Views PDF: 455
COST-EFFECTIVENESS ANALYSIS OF INTRODUCING BUDESONIDE/ FORMOTEROL IN VIETNAMESE PATIENTS WITH MODERATE TO SEVERE ASTHMA
Main Article Content
Abstract
Objectives: This study evaluated the cost-effectiveness of budesonide/formoterol maintenance and reliever therapy (SMART) compared with ICS/LABA plus as-needed SABA in the treatment of moderate to severe asthma in Vietnam. Research methods: The Markov model was selected for cost-effectiveness analysis, including two scenarios to evaluate SMART therapy compared with Salmeterol/Fluticasone 25/125 µg and 25/250 µg plus Salbutamol as-needed. Clinical efficacy data were obtained from a systematic review and meta-analysis study. Cost data were collected from the burden of disease study in Vietnam and from the website of the Drug Administration of Vietnam. Deterministic and probabilistic sensitivity analysis were conducted to assess the robustness of the model. Results: Budesonide/Formoterol maintenance and reliever therapy (SMART) dominated the comparator resulting in an increase of 0.005 QALYs in both scenarios and a reduction of 209.5 and 181.7 million VND treatment costs in scenarios one and two, respectively. Deterministic and probabilistic sensitivity analysis both confirmed that in most cases, Budesonide/Formoterol were both cost-effective. Conclusion: In patients with moderate to severe asthma, SMART therapy was more effective while less costly than the comparator. Decision-makers in Vietnam can use this health economics evidence to make better decisions regarding the management of moderate to severe asthma.
Article Details
Keywords
Budesonide/Formoterol, Asthma, Cost-effectiveness analysis, SMART
References
2. Phạm Huy Tuấn Kiệt, Vũ Văn Giáp, Nguyễn Thị Thanh Hà. Chi phí y tế trực tiếp trong điều trị hen theo phân loại GINA dựa trên dữ liệu lớn từ Bảo hiểm y tế Việt Nam năm 2019. Tạp chí Y học Việt Nam. 2021; 503(2): 169–72.
3. Lai CK, De Guia TS, Kim YY, et al. Asthma control in the Asia-Pacific region: the Asthma Insights and Reality in Asia-Pacific Study. The Journal of allergy and clinical immunology. 2003; 111(2): 263–268.
4. Sobieraj DM, Weeda ER, Coleman CI, et al. Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy with Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis. JAMA. 2018; 319(14): 1485–1496.
5. Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Primary care respiratory journal: journal of the General Practice Airways Group. 2007; 16(1): 22–27.
6. Miller E, Sears MR, McIvor A, Liovas A. Canadian economic evaluation of budesonide-formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian respiratory journal. 2007; 14(5): 269–275.
7. Loh LC, Lim BK, Raman S, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in moderate-to-severe asthma: a real-life effectiveness study of Malaysian patients. The Medical journal of Malaysia. 2008; 63(3): 188–192.
8. Wickstrøm J, Dam N, Malmberg I, et al. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark - cost-effectiveness analysis based on five randomised controlled trials. The clinical respiratory journal. 2009; 3(3): 169–180.